Latest & greatest articles for venlafaxine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on venlafaxine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on venlafaxine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for venlafaxine

21. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis

The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis Bauer M, Tharmanathan P, Volz HP, Moeller HJ, Freemantle N CRD summary The authors concluded that venlafaxine (...) was clinically effective in achieving therapeutic response and remission in patients with major depression. There were limitations in reporting of review methods, but overall the authors’ conclusions reflected the evidence presented and were likely to be reliable. Authors' objectives To evaluate the efficacy and tolerability of venlafaxine for the treatment of major depressive disorders compared with tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs). Searching MEDLINE

DARE.2009

23. Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study

Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study 18344727 2008 03 17 2008 05 27 2015 11 19 0271-0749 28 2 2008 Apr Journal of clinical psychopharmacology J Clin Psychopharmacol Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study. 171-81 10.1097/JCP.0b013e318166c4e6 Practice guidelines for the initial treatment of bipolar II (BP (...) II) major depressive episode (MDE) recommend mood stabilizer (MS) monotherapy or combined MS plus antidepressant drug (AD) therapy. We hypothesized that initial AD monotherapy would be superior to MS monotherapy for BP II MDE with a low hypomanic switch rate. Bipolar II MDE patients were randomized to a 12-week open-label treatment with either venlafaxine monotherapy (n = 43) or lithium carbonate monotherapy (n = 40). The primary outcome measure was the 28-item Hamilton Depression Rating Scale

EvidenceUpdates2008

24. The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder

The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder 18284439 2008 03 07 2008 07 31 2017 02 20 1742-1241 62 4 2008 Apr International journal of clinical practice Int. J. Clin. Pract. The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder. 623-32 10.1111/j.1742-1241.2008.01711.x The Prevention of Recurrent Episodes of Depression with venlafaxine XR for Two Years trial has reported (...) advantages with maintenance treatment for patients with recurrent depressive disorder. The aim of this study was to assess the cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder, based on a recent clinical trial. A Markov simulation model was constructed to assess the cost-utility of maintenance treatment for 2 years in recurrently depressed patients in Sweden. Risk of relapse and recurrence was based on a recent randomised clinical trial assessing

EvidenceUpdates2008 Full Text: Link to full Text with Trip Pro

25. Pregabalin and venlafaxine improve symptoms of generalised anxiety disorder

Pregabalin and venlafaxine improve symptoms of generalised anxiety disorder Pregabalin and venlafaxine improve symptoms of generalised anxiety disorder | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Pregabalin and venlafaxine improve symptoms of generalised anxiety disorder Article Text Therapeutics Pregabalin and venlafaxine improve symptoms of generalised anxiety disorder Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish to reuse any or all of this article please use the link below

Evidence-Based Mental Health2008

26. Higher dose venlafaxine may improve response compared with standard doses in people with major depressive disorder and intolerance or non-responsiveness to SSRIs

Higher dose venlafaxine may improve response compared with standard doses in people with major depressive disorder and intolerance or non-responsiveness to SSRIs Higher dose venlafaxine may improve response compared with standard doses in people with major depressive disorder and intolerance or non-responsiveness to SSRIs | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Higher dose venlafaxine may improve response compared with standard doses in people with major depressive disorder and intolerance or non-responsiveness to SSRIs Article Text

Evidence-Based Mental Health2008

27. The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation

The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation Kongsakon R, Bunchapattanasakda C Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of escitalopram versus fluoxetine and venlafaxine for the treatment of major depressive disorder. The authors concluded that escitalopram was more

NHS Economic Evaluation Database.2008

28. The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder

The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder Sobocki P, Ekman M, Ovanfors A, Khandker R, Jonsson B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of a two-year maintenance treatment with venlafaxine for the treatment of adult patients with recurrent major depressive disorders. Venlafaxine was a cost-effective alternative to no treatment in this patient population from the perspective

NHS Economic Evaluation Database.2008

29. Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis

Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis Weinmann S, Becker T, Koesters M CRD summary This review, which evaluated the efficacy of venlafaxine compared to selective serotonin re-uptake inhibitors (SSRIs), concluded that venlafaxine was not clinically superior. The authors' conclusions (...) were appropriate and likely to be reliable, although the authors were unable to investigate whether the effectiveness of the treatments varied with severity of depression. Authors' objectives To evaluate the efficacy of venlafaxine compared to selective serotonin re-uptake inhibitors (SSRIs) and assess the influence of methodological factors on the effect sizes. Searching MEDLINE, EMBASE, PsycINFO, PSYNDEX and the Cochrane Central Register of Controlled Trials were searched up to March 2007. Two

DARE.2008

30. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.

Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. 18314433 2008 03 03 2008 03 07 2016 11 22 1538-3598 299 8 2008 Feb 27 JAMA JAMA Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. 901-13 10.1001/jama.299.8.901 Only about 60% of adolescents (...) that had not responded to a 2-month initial treatment with an SSRI, conducted at 6 US academic and community clinics from 2000-2006. Twelve weeks of: (1) switch to a second, different SSRI (paroxetine, citalopram, or fluoxetine, 20-40 mg); (2) switch to a different SSRI plus cognitive behavioral therapy; (3) switch to venlafaxine (150-225 mg); or (4) switch to venlafaxine plus cognitive behavioral therapy. Clinical Global Impressions-Improvement score of 2 or less (much or very much improved

JAMA2008 Full Text: Link to full Text with Trip Pro

31. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation.

Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation. Major depressive disorder (MDD), a prevalent and serious mental illness, is associated with a substantial disease and economic burden. Long-term pharmacotherapy is often necessary; selective serotonin reuptake inhibitors (SSRIs) or the serotonin-noradrenaline reuptake inhibitor venlafaxine are the most frequently prescribed medications (...) in patients with moderate-to-severe depressive symptoms. This article reviews head-to-head clinical studies and health economic models comparing the efficacy, tolerability and cost-effectiveness of escitalopram, a dual-action selective inhibitor of serotonin reuptake, and the extended-release (XR) formulation of venlafaxine. While there has been some evidence that conventional SSRIs are inferior to venlafaxine in terms of efficacy, escitalopram was at least as effective as venlafaxine XR in reducing

EvidenceUpdates2007

32. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study.

Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. OBJECTIVE: To compare the risk of suicide in adults using the antidepressant venlafaxine compared with citalopram, fluoxetine, and dothiepin. DESIGN: Retrospective cohort study. SETTING: UK General Practice Research Database. PARTICIPANTS: 219,088 patients, aged 18-89 years, who were prescribed venlafaxine, citalopram, fluoxetine, or dothiepin from 1995 to 2005. MAIN OUTCOME (...) MEASURES: Completed suicide and attempted suicide. RESULTS: Venlafaxine users had a higher burden of risk factors for suicide, including previous suicide attempts and proxies for severe depression or depression that was difficult to treat. In the analysis for completed suicides, unadjusted and adjusted hazard ratios for venlafaxine compared with citalopram were 2.44 (95% confidence interval 1.12 to 5.31) and 1.70 (0.76 to 3.80), for venlafaxine compared with fluoxetine were 2.85 (1.37 to 5.94) and 1.63

BMJ2007 Full Text: Link to full Text with Trip Pro

33. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care

A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary (...) care Sorensen J, Stage K B, Damsbo N, Le Lay A, Hemels M E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of escitalopram in comparison with generic citalopram and venlafaxine in the primary

NHS Economic Evaluation Database.2007

34. Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram

Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram Article Text Therapeutics Major depressive disorder: similar remission rates

Evidence-Based Mental Health2006

35. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. 16554525 2006 03 23 2006 04 07 2015 11 19 1533-4406 354 12 2006 Mar 23 The New England journal of medicine N. Engl. J. Med. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. 1231-42 After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another. We (...) randomly assigned 727 adult outpatients with a nonpsychotic major depressive disorder who had no remission of symptoms or could not tolerate the SSRI citalopram to receive one of the following drugs for up to 14 weeks: sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg, sertraline (238 patients) at a maximal daily dose of 200 mg, or extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg. The study was conducted in 18 primary and 23 psychiatric care

NEJM2006

36. Venlafaxine offers no benefit over sertraline and is less well tolerated in depressed nursing home residents

Venlafaxine offers no benefit over sertraline and is less well tolerated in depressed nursing home residents Venlafaxine offers no benefit over sertraline and is less well tolerated in depressed nursing home residents | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Venlafaxine offers no benefit over sertraline and is less well tolerated in depressed nursing home residents Article Text Therapeutics Venlafaxine offers no benefit over sertraline and is less well tolerated in depressed nursing home residents Free Lon S Schneider , MD Statistics

Evidence-Based Mental Health2005

37. Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials

Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials Vis P M, Van Baardewijk M, Einarson T R CRD summary This generally well-conducted review concluded that duloxetine and venlafaxine (...) -XR are effective, compared with placebo, for the treatment of major depressive disorder. Venlafaxine tends to have a favourable trend in remission and response rates compared with duloxetine. Conclusions relating to comparisons with placebo seem reliable, but the conclusion regarding the superiority of venlafaxine over duloxetine is not fully supported by the results. Authors' objectives To compare indirectly the efficacy and safety of extended-release (XR) venlafaxine and duloxetine

DARE.2005

38. Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalised anxiety disorder in the United Kingdom

Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalised anxiety disorder in the United Kingdom Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalised anxiety disorder in the United Kingdom Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalised anxiety disorder in the United Kingdom Guest J F, Russ J, Lenox-Smith A Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared the effectiveness and costs of venlafaxine XL (Efexor XL) and diazepam for the treatment of generalised anxiety disorder (GAD) among non-depressed patients. Patients received either 75 mg venlafaxine XL once daily or 5 mg diazepam 3

NHS Economic Evaluation Database.2005

39. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder

Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder Fernandez J L, Montgomery S, Francois C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of escitalopram, a selective serotonin reuptake inhibitor, in the treatment of major depressive disorder (MMD). The comparator was venlafaxine RX, a serotonin noradrenaline (norepinephrine) reuptake inhibitor with established efficacy in MMD. Type of intervention Treatment. Economic study type Cost-utility analysis

NHS Economic Evaluation Database.2005

40. A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium

A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium Demyttenaere K, Hemels M E, Hudry J, Annemans L Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health technologies compared were escitalopram (10 - 20 mg/day), citalopram (20 - 40 mg/day) and venlafaxine (75 - 150 mg/day) as first-line treatment for major depressive disorder (MDD). MDD was defined as baseline

NHS Economic Evaluation Database.2005